盖诺联合顺铂治疗中、晚期食管癌的临床疗效观察

Clinical Study of Vinorelbine Combined with Cisplatin in the Treatment of Advanced Esophageal Cancer

目的观察盖诺（NVB）联合顺铂（CDDP）的NP方案治疗食管癌的疗效和毒副反应。方法对46例食管癌患者应用NP方案进行治疗，其中NVB2530mg／m^2，静脉滴入，d1、ds给药；DDP30mg／m^2，静脉冲入，d1～3给药，21～28天为1周期，每例至少治疗2个周期。结果46例患者中总有效率（RR）为45．7％（21／46），其中CR2．2％（1／46），PR43．5％（20／46），SD34．8％（16／46），PD19．6％（9／46），中位生存期9．6个月（2424个月），主要毒副反应为骨髓抑制及消化道反应。结论盖诺联合顺铂治疗食管癌疗效确切，毒副反应可以耐受。

Objective To evaluate the efficiency and toxicity of combination chemotherapy with vinorelbine and cisplain in the treatment of advanced esophageal cancer. Methods Forty six cases were treated with NP regimen, NVB 25-30mg/m^2 ,iv, d1 and ds ; DDP 30mg/m^2 ,iv, from d1 to d3. The cycle was repeated every 21-28 days. Results The overall response rate was 45.7% （21/46）, with CR 2.2% （1/46）, PR 43.5%（20/46）, SD34. 8%（16/46）, and PD 19. 6% （9/46）. The median overall survival of the whole group was 9. 6 months （2-24 months）. The major toxicity and side effects were myelosuppression, nausea and vomiting, which were mild to moderate. Conclusion NP regimen is effective for the advanced esophageal cancer and the toxicity and side effects are tolerable.